Lyra Therapeutics Inc. logo

Lyra Therapeutics (LYRA) stock

LYRA · Lyra Therapeutics Inc. · NASDAQ

Website

What is the latest news on LYRA stock?

INSIDERago
Director Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)

4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

All LYRA news

Are insiders buying or selling LYRA?

No LYRA insider has reported a purchase or sale in the last 90 days. The last trade on file: Jason Cavalier sold $3K, reported on Jan 8, 2026.

LYRA insider trades

Latest news

25 items

Lyra Therapeutics Inc. (LYRA) is a Medical/Dental Instruments company listed on NASDAQ. There were no new wire items for LYRA in the last 30 days. The most recent was published May 15, 2026.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA FAQ

7 questions
  • What does Lyra Therapeutics Inc. do?
    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients...
  • Where does LYRA stock trade?
    Lyra Therapeutics Inc. (LYRA) is listed on NASDAQ.
  • What sector and industry is LYRA in?
    Lyra Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.
  • When did Lyra Therapeutics Inc. go public?
    Lyra Therapeutics Inc. (LYRA) completed its IPO in 2020.
  • What are analysts saying about LYRA?
    Across the last 7 analyst actions on Lyra Therapeutics Inc., there were 0 upgrades and 4 downgrades. The most recent action was from H.C. Wainwright: Neutral with a $2.00 price target on 2024-05-07.
  • What companies are similar to LYRA?
    Notable peers in the same industry include BSX (Boston Scientific Corporation), RMD (ResMed Inc.), MDLN (Medline Inc.), DXCM (DexCom Inc.), MMM (3M Company). Compare LYRA side-by-side with any of them on Quantisnow.
  • How can I track LYRA on Quantisnow?
    Quantisnow aggregates Lyra Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LYRA to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change